Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug (2)
[Posted 02/13/2020]
AUDIENCE: Patient, Health Professional, Pharmacy
Health Professionals
Health professionals should stop prescribing and dispensing lorcaserin to patients. Contact patients currently taking lorcaserin, inform them of the increased occurrence of cancer seen in the clinical trial, and ask them to stop taking the medicine. Discuss alternative weight-loss medicines or strategies with your patients.
FDA is not recommending special screening for patients who have taken lorcaserin. As with any individual patient, regardless of prior lorcaserin treatment, standard screening recommendations for cancer should be implemented.
Read more about the MedWatch Safety Alert, including a link to the FDA Drug Safety Communication, at:
https://www.fda.gov/safety/medical-product-safety-information/belviq-belviq-xr-lorcaserin-eisai-drug-safety-communication-fda-requests-withdrawal-weight-loss-drug?utm_campaign=FDA%20MedWatch%20-%20Belviq%2C%20Belviq%20XR%20%28lorcaserin%29%3A%20DSC%20-%20FDA%20Requests%20Withdrawal%20of%20Weight-Loss%20Drug&utm_medium=email&utm_source=Eloqua
醫療專業人員：
醫療專業人員應停止再開立或調劑lorcaserin給病人，並聯繫正在服用lorcaserin之病人，告知此藥品之安全性臨床試驗中發現會增加癌症的發生率，並要求他們停止服藥。請與病人討論替代減肥藥物或之後的體重管理策略。
美國FDA不建議對服用lorcaserin的病人進行特殊篩檢。如同其他一般病人，無論先前是否使用lorcaserin治療，應實行癌症標準篩檢的建議。
更多相關訊息與連結請參考FDA網址：https://reurl.cc/QdbZe5
（全文完）
資料來源：美國FDA之藥物安全警訊
資料提供：台大醫院藥劑部
回首頁 |